Nvidia, Abridge collaborate to develop healthcare-specific AI model - Fierce Healthcare

Ah, Nvidia and Abridge are joining forces to train a 'healthcare-specific foundation model tailored to clinical conversations' — because what could possibly go wrong when you let a company whose main business is selling shovels for the AI gold rush loose on something as forgiving as, say, medical diagnosis? The press release promises 'improved accuracy and reliability of clinical workflows,' which sounds lovely until you remember that 'improved' is a relative term when the baseline is a wildly hallucinatory general-purpose LLM. One can almost hear the liability lawyers sharpening their pencils as Nvidia and Abridge barrel into the domain where a single hallucination could mean a missed heart attack or a wrong prescription.

Abridge, for those not following closely, is the startup that transcribes doctor-patient visits — a task so fraught with privacy and accuracy landmines that it's a miracle anyone attempts it commercially. Now they're doubling down with a custom foundation model, presumably trained on heaps of sensitive clinical data, because nothing says 'patient confidentiality' quite like handing your conversations to a chip manufacturer's GPU farm. The twist? Nvidia is effectively creating a feedback loop: they sell the hardware, they help train the software, and they'll almost certainly sell the inference chips for the same model. Vertical integration in healthcare — what could possibly go wrong?

The real joy is watching how this will interact with the existing regulatory landscape. The FDA has barely figured out how to certify software as a medical device when it's static; throwing a continuously updating foundation model into the mix is a recipe for regulatory chaos. But hey, 'accuracy and reliability' are being improved, so who needs clinical trials when you have a press release? Nvidia's CEO Jensen Huang probably already has a slide deck ready for the next earnings call, forecasting a multi-trillion-dollar 'healthcare AI opportunity' that somehow never seems to improve patient outcomes, only GPU sales.